[go: up one dir, main page]

WO2024040025A3 - Th2 vaccine-based prevention and treatment of inflammation in obesity - Google Patents

Th2 vaccine-based prevention and treatment of inflammation in obesity Download PDF

Info

Publication number
WO2024040025A3
WO2024040025A3 PCT/US2023/072164 US2023072164W WO2024040025A3 WO 2024040025 A3 WO2024040025 A3 WO 2024040025A3 US 2023072164 W US2023072164 W US 2023072164W WO 2024040025 A3 WO2024040025 A3 WO 2024040025A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
mice
vaccine
treatment
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/072164
Other languages
French (fr)
Other versions
WO2024040025A2 (en
Inventor
Mary L. Disis
Denise CECIL
Lauren CORULLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Priority to CA3264592A priority Critical patent/CA3264592A1/en
Priority to KR1020257008124A priority patent/KR20250051700A/en
Priority to AU2023325021A priority patent/AU2023325021A1/en
Priority to JP2025510363A priority patent/JP2025529838A/en
Priority to CN202380060505.4A priority patent/CN119730869A/en
Priority to EP23855592.4A priority patent/EP4572780A2/en
Publication of WO2024040025A2 publication Critical patent/WO2024040025A2/en
Publication of WO2024040025A3 publication Critical patent/WO2024040025A3/en
Priority to MX2025002034A priority patent/MX2025002034A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Overexpressed proteins associated with inflammatory adipocytes have been demonstrated in TNF-a inflamed adipocyte lines derived from humans and mice as well as in visceral fat derived from mice fed an inflammatory-generating high fat high sucrose diet. The adipocyte-associated proteins are immunogenic in humans and mice, and can be used as a vaccine that drives Type II T-cells to inflammatory adipose tissue. Compositions and methods for the prevention and treatment of disease associated with metabolic obesity, including cancer, such as breast cancer, and non-alcoholic fatty liver disease (NAFLD) are provided.
PCT/US2023/072164 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity Ceased WO2024040025A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3264592A CA3264592A1 (en) 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity
KR1020257008124A KR20250051700A (en) 2022-08-19 2023-08-14 TH2 vaccine-based prevention and treatment of inflammation in obesity
AU2023325021A AU2023325021A1 (en) 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity
JP2025510363A JP2025529838A (en) 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity
CN202380060505.4A CN119730869A (en) 2022-08-19 2023-08-14 Prevention and treatment of obesity inflammation based on TH2 vaccine
EP23855592.4A EP4572780A2 (en) 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity
MX2025002034A MX2025002034A (en) 2022-08-19 2025-02-19 Th2 vaccine-based prevention and treatment of inflammation in obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263371999P 2022-08-19 2022-08-19
US63/371,999 2022-08-19

Publications (2)

Publication Number Publication Date
WO2024040025A2 WO2024040025A2 (en) 2024-02-22
WO2024040025A3 true WO2024040025A3 (en) 2024-04-25

Family

ID=89942345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072164 Ceased WO2024040025A2 (en) 2022-08-19 2023-08-14 Th2 vaccine-based prevention and treatment of inflammation in obesity

Country Status (8)

Country Link
EP (1) EP4572780A2 (en)
JP (1) JP2025529838A (en)
KR (1) KR20250051700A (en)
CN (1) CN119730869A (en)
AU (1) AU2023325021A1 (en)
CA (1) CA3264592A1 (en)
MX (1) MX2025002034A (en)
WO (1) WO2024040025A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038990A1 (en) * 2006-09-25 2008-04-03 Sj Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
WO2009149931A2 (en) * 2008-06-11 2009-12-17 Technische Universität Dresden Fatty acid binding protein in the pathogenesis of cardiac dysfunction
US20200355695A1 (en) * 2017-02-28 2020-11-12 Pierce Biotechnology, Inc. Detection and quantification of ras-raf-mapk pathway proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038990A1 (en) * 2006-09-25 2008-04-03 Sj Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
WO2009149931A2 (en) * 2008-06-11 2009-12-17 Technische Universität Dresden Fatty acid binding protein in the pathogenesis of cardiac dysfunction
US20200355695A1 (en) * 2017-02-28 2020-11-12 Pierce Biotechnology, Inc. Detection and quantification of ras-raf-mapk pathway proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QIU ET AL.: "Identification of differentially expressed genes in omental adipose tissues of obese patients by suppression subtractive hybridizatio n", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 352, no. 2, 12 January 2007 (2007-01-12), pages 469 - 478, XP029000081, DOI: 10.1016/j.bbrc.2006.11.049 *

Also Published As

Publication number Publication date
AU2023325021A1 (en) 2025-03-27
JP2025529838A (en) 2025-09-09
WO2024040025A2 (en) 2024-02-22
EP4572780A2 (en) 2025-06-25
KR20250051700A (en) 2025-04-17
MX2025002034A (en) 2025-04-02
CA3264592A1 (en) 2024-02-22
CN119730869A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
Mei et al. Protective effect of chitooligosaccharides against cyclophosphamide-induced immunosuppression in mice
Gao et al. Protective effects of Ulva pertusa polysaccharide and polysaccharide‑iron (III) complex on cyclophosphamide induced immunosuppression in mice
Fan et al. Partial characterization and anti-tumor activity of an acidic polysaccharide from Gracilaria lemaneiformis
Wu et al. Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice
Ebrahimi-Mameghani et al. Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial
Huang et al. A novel polysaccharide from the seeds of Plantago asiatica L. induces dendritic cells maturation through toll-like receptor 4
Jiao et al. Anti-tumour and immunomodulatory activities of oligosaccharides isolated from Panax ginseng CA Meyer
Dong et al. Structural characterization of a water-soluble polysaccharide from Angelica dahurica and its antitumor activity in H22 tumor-bearing mice
Janczyk et al. Nutritional value of Chlorella vulgaris: effects of ultrasonication and electroporation on digestibility in rats
Li et al. Natural constituents from food sources as therapeutic agents for obesity and metabolic diseases targeting adipose tissue inflammation
Nworu et al. Immunomodulatory and immunorestorative activities of β-d-glucan-rich extract and polysaccharide fraction of mushroom, Pleurutus tuberregium
Li et al. Chemical composition and antioxidant activities in immumosuppressed mice of polysaccharides isolated from Mosla chinensis Maxim cv. Jiangxiangru
Jiang et al. Preliminary characterization and immunostimulatory activity of polysaccharides from Glossaulax didyma
Jo et al. Polysaccharide isolated from fermented barley activates innate immune system and anti-tumor metastasis in mice
Wong et al. The immunostimulating activities of anti-tumor polysaccharides from Pseudostellaria heterophylla
Xie et al. Characterization and antitumor activities of a water-soluble polysaccharide from Ampelopsis megalophylla
Gonciarz et al. The influence of Salvia cadmica Boiss. extracts on the M1/M2 polarization of macrophages primed with Helicobacter pylori lipopolysaccharide in conjunction with NF-kappa B activation, production of cytokines, phagocytic activity and total DNA methylation
Guan et al. Components of heat-treated Helianthus annuus L. pectin inhibit tumor growth and promote immunity in a mouse CT26 tumor model
WO2024040025A3 (en) Th2 vaccine-based prevention and treatment of inflammation in obesity
Park et al. Anti-obesity potential of enzymatic fragments of hyaluronan on high-fat diet-induced obesity in C57BL/6 mice
He et al. Immunomodulatory activities of five clinically used Chinese herbal polysaccharides.
Mallick et al. Antitumor properties of a heteroglucan isolated from Astraeus hygrometricus on Dalton’s lymphoma bearing mouse
Jeong et al. Antitumor and immunomodulating activities of endo-biopolymers obtained from a submerged culture of Pleurotus eryngii
MX2022013018A (en) METHODS TO REDUCE MUSCLE ATROPHY AND/OR PROMOTE MUSCLE REGENERATION.
Safari et al. Immunomodulatory effects of shark cartilage: Stimulatory or anti-inflammatory

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855592

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380060505.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2025510363

Country of ref document: JP

Ref document number: MX/A/2025/002034

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 202517020261

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: AU2023325021

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20257008124

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020257008124

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2023855592

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023855592

Country of ref document: EP

Effective date: 20250319

ENP Entry into the national phase

Ref document number: 2023325021

Country of ref document: AU

Date of ref document: 20230814

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 202517020261

Country of ref document: IN

Ref document number: 202380060505.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: MX/A/2025/002034

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1020257008124

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855592

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2023855592

Country of ref document: EP